Drug Profile
Imatinib ophthalmic - Avixgen
Alternative Names: AVI 4015Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Avixgen
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Discoidin domain receptor 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Dry eyes
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Dry-eyes(In volunteers) in South Korea (Ophthalmic, Drops)
- 02 Jul 2023 Phase-II clinical trials in Dry eyes (Ophthalmic) (Avixgen pipeline July 2023)
- 16 Jun 2021 Avixgene plans a pre-IND meeting with the US FDA for Dry eyes